{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:20:58Z","timestamp":1792815658879,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","semarthritisrheumatism.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.semarthrit.2015.02.002","type":"journal-article","created":{"date-parts":[[2015,2,20]],"date-time":"2015-02-20T00:37:18Z","timestamp":1424392638000},"page":"48-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":89,"title":["Interleukin-6 in ANCA-associated vasculitis: Rationale for successful treatment with tocilizumab"],"prefix":"10.1016","volume":"45","author":[{"given":"Alvise","family":"Berti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Cavalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Campochiaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Guglielmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Baldissera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Cappio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Sabbadini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Doglioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Dagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2015.02.002_bib1","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1056\/NEJM199711203372106","article-title":"Small-vessel vasculitis","volume":"337","author":"Jennette","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2015.02.002_bib2","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nrrheum.2010.158","article-title":"ANCA-associated vasculitides\u2014advances in pathogenesis and treatment","volume":"6","author":"Chen","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.02.002_bib3","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.rdc.2010.04.003","article-title":"Microscopic polyangiitis","volume":"36","author":"Chung","year":"2010","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.semarthrit.2015.02.002_bib4","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1056\/NEJM197104292841703","article-title":"Cyclophosphamide therapy in Wegener\u2019s granulomatosis","volume":"284","author":"Novack","year":"1971","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2015.02.002_bib5","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2015.02.002_bib6","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2015.02.002_bib7","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/art.21869","article-title":"Solid malignancies among patients in the Wegener\u2019s Granulomatosis Etanercept Trial","volume":"54","author":"Stone","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.02.002_bib8","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa041884","article-title":"Etanercept plus standard therapy for Wegener\u2019s granulomatosis","volume":"352","author":"Wegener\u2019s Granulomatosis Etanercept Trial (WGET) Research Group","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2015.02.002_bib9","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nrrheum.2013.161","article-title":"Immune mechanisms in mediaum and large-vessel vasculitis","volume":"9","author":"Weyand","year":"2013","journal-title":"Nat Rev Rheumatl"},{"key":"10.1016\/j.semarthrit.2015.02.002_bib10","first-page":"256","article-title":"Serum myeloperoxidase and serum cytokines in anti-myeloperoxidase antibody-associated glomerulonephritis","volume":"40","author":"Arimura","year":"1993","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.semarthrit.2015.02.002_bib11","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/09629350400003100","article-title":"Circulating cytokine profile in anti-neutrophilic cytoplasmatic autoantibody-associated vasculitis: prediction of outcome?","volume":"13","author":"Ohlsson","year":"2004","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.semarthrit.2015.02.002_bib12","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2169\/internalmedicine.32.189","article-title":"Distinct responses of interleukin-6 and other laboratory parameters to treatment in a patient with Wegener\u2019s granulomatosis","volume":"32","author":"Nakahama","year":"1993","journal-title":"Intern Med"},{"key":"10.1016\/j.semarthrit.2015.02.002_bib13","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1136\/ard.58.4.237","article-title":"Monocyte activation in patients with Wegener\u2019s granulomatosis","volume":"58","author":"Muller Kobold","year":"1999","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.02.002_bib14","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0385-8146(01)00097-9","article-title":"Serum levels of soluble adhesion molecules ICAM-1, VCAM-1 and E-selectin in patients with Wegener\u2019s granulomatosis","volume":"28","author":"Ohta","year":"2001","journal-title":"Auris Nasus Larynx"},{"key":"10.1016\/j.semarthrit.2015.02.002_bib15","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/art.20002","article-title":"Inflammation and arterial stiffness in systemic vasculitis: a model of vascular inflammation","volume":"50","author":"Booth","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.02.002_bib16","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1007\/s10157-011-0423-3","article-title":"A case of a 6-year-old girl with anti-neutrophil cytoplasmic autoantibody-negative pauci-immune crescentic glomerulonephritis","volume":"15","author":"Shimizu","year":"2011","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.semarthrit.2015.02.002_bib17","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","article-title":"Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease","volume":"112","author":"Nishimoto","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2015.02.002_bib18","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/art.1780370206","article-title":"Nomenclature of systemic vasculitides. Proposal of an international consensus conference","volume":"37","author":"Jennette","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.02.002_bib19","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1136\/ard.2006.054593","article-title":"Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies","volume":"66","author":"Watts","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.02.002_bib20","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1093\/ndt\/gfi117","article-title":"A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis","volume":"20","author":"Joy","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semarthrit.2015.02.002_bib21","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/1529-0131(200104)44:4<912::AID-ANR148>3.0.CO;2-5","article-title":"A disease-specific activity index for Wegener\u2019s granulomatosis: modification of the Birmingham Vasculitis Activity Score","volume":"44","author":"Stone","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.02.002_bib22","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/art.1780400222","article-title":"Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides","volume":"40","author":"Exley","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.02.002_bib23","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0895-4356(98)00081-X","article-title":"Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project","volume":"51","author":"Ware","year":"1998","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.semarthrit.2015.02.002_bib24","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/rheumatology\/ker222","article-title":"Complete remission of myeloperoxidase-anti-neutrophil cytoplasmic antibody-associated crescentic glomerulonephritis complicated with rheumatoid arthritis using a humanized anti-interleukin 6 receptor antibody","volume":"50","author":"Sumida","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2015.02.002_bib25","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s10067-013-2457-2","article-title":"Successful treatment of refractory aortitis in antineutrophil cytoplasmic antibody-associated vasculitis using tocilizumab","volume":"33","author":"Takenaka","year":"2014","journal-title":"Clin Rheumatol"},{"issue":"Suppl. 3","key":"10.1016\/j.semarthrit.2015.02.002_bib26","doi-asserted-by":"crossref","first-page":"S233","DOI":"10.1186\/ar565","article-title":"The paradigm of IL-6: from basic science to medicine","volume":"4","author":"Naka","year":"2002","journal-title":"Arthritis Res"},{"key":"10.1016\/j.semarthrit.2015.02.002_bib27","doi-asserted-by":"crossref","first-page":"912562","DOI":"10.1155\/2013\/912562","article-title":"Design of the tocilizumab in giant cell arteritis trial","volume":"2013","author":"Unizony","year":"2013","journal-title":"Int J Rheumatol"},{"issue":"Suppl. 82","key":"10.1016\/j.semarthrit.2015.02.002_bib28","first-page":"S79","article-title":"Tocilizumab in refractory aortitis: study on 16 patients and literature review","volume":"32","author":"Loricera","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.02.002_bib29","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.3899\/jrheum.130536","article-title":"Treatment of refractory Takayasu arteritis with tocilizumab: 7 Italian patients from a single referral center","volume":"40","author":"Tombetti","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.02.002_bib30","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/rheumatology\/ker296","article-title":"Tocilizumab: a novel therapy for patients with large-vessel vasculitis","volume":"51","author":"Salvarani","year":"2012","journal-title":"Rheumatology (Oxford)"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017215000128?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017215000128?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T20:57:30Z","timestamp":1537822650000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017215000128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0049017215000128"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2015.02.002","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725423450.793519129","asserted-by":"object"}]},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interleukin-6 in ANCA-associated vasculitis: Rationale for successful treatment with tocilizumab","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2015.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}